• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib.

作者信息

Doi Ayako, Kuboki Yasutoshi, Shitara Kohei, Fukuoka Shota, Bando Hideaki, Okamoto Wataru, Kojima Takashi, Doi Toshihiko, Ohtsu Atsushi, Yoshino Takayuki

机构信息

Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.

出版信息

Clin Colorectal Cancer. 2016 Dec 28. doi: 10.1016/j.clcc.2016.11.003.

DOI:10.1016/j.clcc.2016.11.003
PMID:28089507
Abstract
摘要

相似文献

1
Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib.5例接受瑞戈非尼治疗的结直肠癌患者出现胃肠道穿孔和瘘管形成
Clin Colorectal Cancer. 2016 Dec 28. doi: 10.1016/j.clcc.2016.11.003.
2
Intestinal Perforation in a Patient with Colon Cancer during Treatment with Regorafenib: A Case Report and Review of the Literature.结直肠癌患者接受regorafenib 治疗时发生肠穿孔：病例报告及文献复习。
Tohoku J Exp Med. 2021 Jul;254(3):207-211. doi: 10.1620/tjem.254.207.
3
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.二线化疗失败后 ≥ 75 岁转移性结直肠癌（mCRC）患者采用 2/1 方案应用regorafenib 的疗效和安全性。
Clin Colorectal Cancer. 2018 Dec;17(4):307-312. doi: 10.1016/j.clcc.2018.02.005. Epub 2018 Feb 21.
4
Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?regorafenib 或重新挑战化疗：在转移性结直肠癌的三线治疗中哪种更有效？
Cancer Chemother Pharmacol. 2019 Jan;83(1):115-122. doi: 10.1007/s00280-018-3713-6. Epub 2018 Oct 29.
5
Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.regorafenib 在抗血管生成初治和化疗耐药的晚期结直肠癌患者中的疗效：一项 IIb 期试验的结果。
Oncologist. 2019 Sep;24(9):1180-1187. doi: 10.1634/theoncologist.2019-0067. Epub 2019 Jun 7.
6
Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.瑞戈非尼联合化疗作为转移性结直肠癌患者二线治疗的疗效和安全性：一项网状Meta分析和系统文献综述
Adv Ther. 2020 Oct;37(10):4233-4248. doi: 10.1007/s12325-020-01447-2. Epub 2020 Aug 8.
7
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data.瑞戈非尼与TAS-102治疗化疗难治性转移性结直肠癌（mCRC）患者疗效及安全性的回顾性研究：一项多机构真实世界临床数据研究
Clin Colorectal Cancer. 2021 Sep;20(3):227-235. doi: 10.1016/j.clcc.2021.06.002. Epub 2021 Jun 10.
8
Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.瑞戈非尼：一种用于治疗结直肠癌和胃肠道间质瘤的新型多靶点酪氨酸激酶抑制剂。
Ann Pharmacother. 2013 Dec;47(12):1685-96. doi: 10.1177/1060028013509792. Epub 2013 Nov 1.
9
Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report.抗 PD-1 药物和regorafenib 导致微卫星稳定转移性结直肠癌严重多系统不良事件：一例报告。
Immunotherapy. 2021 Nov;13(16):1317-1323. doi: 10.2217/imt-2020-0327. Epub 2021 Aug 9.
10
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.regorafenib 治疗标准治疗后进展的转移性结直肠癌患者：大型、单臂、开放标签 IIIb 期 CONSIGN 研究结果。
Oncologist. 2019 Feb;24(2):185-192. doi: 10.1634/theoncologist.2018-0072. Epub 2018 Sep 6.

引用本文的文献

1
Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients.联合放疗与免疫检查点抑制剂治疗转移性或复发性肝细胞癌：108例患者的真实世界研究
Front Immunol. 2025 Aug 4;16:1594577. doi: 10.3389/fimmu.2025.1594577. eCollection 2025.
2
Intestinal Perforation in a patient with peritoneal carcinomatosis from colon cancer treated with Regorafenib. Description of a case and review of the literature.瑞戈非尼治疗结肠癌腹膜转移癌患者并发肠穿孔：一例病例报告及文献复习
Radiol Case Rep. 2024 Feb 29;19(5):2013-2019. doi: 10.1016/j.radcr.2024.02.018. eCollection 2024 May.
3
Risk factors for sepsis in patients with colorectal cancer complicated with gastrointestinal perforation and its impact on prognosis.
结直肠癌合并胃肠道穿孔患者发生脓毒症的危险因素及其对预后的影响。
J Gastrointest Oncol. 2023 Apr 29;14(2):806-814. doi: 10.21037/jgo-23-205.
4
Recurrent hepatogastric fistula during lenvatinib therapy for advanced hepatocellular carcinoma managed by over-the-scope clip closure: a case report.乐伐替尼治疗晚期肝细胞癌期间复发性肝胃瘘经内镜套扎闭合术治疗：一例报告
J Rural Med. 2021 Apr;16(2):102-110. doi: 10.2185/jrm.2020-044. Epub 2021 Apr 1.
5
Lessons learned from successful autologous gastrointestinal reconstruction in patients with intestinal failure: a case series.从成功的肠衰竭患者自体胃肠道重建中吸取的经验教训：病例系列。
BMC Surg. 2021 Feb 4;21(1):73. doi: 10.1186/s12893-021-01075-9.
6
Intestinal perforation after regorafenib usage.瑞戈非尼使用后发生肠穿孔。
Turk J Gastroenterol. 2018 Mar;29(2):245-247. doi: 10.5152/tjg.2018.17316.